US · OABI
OmniAb, Inc.
- Sector
- Healthcare · Biotechnology
- Headquarters
- EmeryVille, CA 94608
- Website
- omniab.com
Price · as of 2024-12-31
$1.40
Market cap 185.11M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $282.70 | +20,092.86% |
| Intrinsic Value(DCF) | $1.77 | +26.43% |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | $8.29 | +492.07% |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | |||||
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | |||||
| 2017 | |||||
| 2018 | |||||
| 2019 | |||||
| 2020 | $0.56 | $0.00 | |||
| 2021 | $10.01 | $44.83 | $0.00 | $0.13 | $0.00 |
| 2022 | $3.28 | $34.52 | $0.00 | $1.71 | $0.00 |
| 2023 | $5.45 | $36.18 | $0.55 | $0.00 | $16.37 |
| 2024 | $3.40 | $282.70 | $0.54 | $0.00 | $8.29 |
AI valuation
Our deep-learning model estimates OmniAb, Inc.'s (OABI) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $282.70
- Current price
- $1.40
- AI upside
- +20,092.86%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$1.77
+26.43% upside
Graham-Dodd
—
— upside
Graham Formula
$8.29
+492.07% upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| OABI | OmniAb, Inc. | $1.40 | 185.11M | +20,093% | +26% | — | +492% | -5.61 | 1.21 | 13.19 | -6.12 | -28.61 | 5.31 | 100.00% | -282.30% | -235.05% | -20.60% | -25.66% | -17.70% | 0.08 | — | 4.52 | 4.29 | 0.09 | 1961.00% | -2275.00% | -600882.00% | -11.94% | -2.63 | -16.47% | 0.00% | 0.00% | 3.92% | -4.18 | -7.51 | 11.81 | 4.59 |
| CCCC | C4 Therapeutics, Inc. | $2.70 | 192.18M | +704% | -21% | — | — | -2.50 | 1.02 | 7.31 | -0.72 | — | 1.02 | 77.81% | -290.68% | -292.08% | -44.44% | -199.27% | -29.63% | 0.23 | — | 7.81 | 7.60 | 0.14 | -1645.00% | 102.00% | 5198.00% | -37.79% | -2.99 | -189.38% | 0.00% | 0.00% | 9.54% | -0.71 | -0.75 | 2.06 | -1.45 |
| CDXS | Codexis, Inc. | $1.01 | 91.23M | +2,411% | +12% | — | +481% | -3.17 | 3.09 | 3.49 | -3.31 | — | 3.21 | 72.55% | -98.61% | -109.99% | -85.03% | -128.77% | -45.72% | 0.89 | — | 4.18 | 3.90 | -0.69 | -2054.00% | -1539.00% | -586.00% | -25.95% | -2.09 | -118.20% | 0.00% | 0.00% | 0.00% | -3.31 | -3.60 | 3.26 | -4.07 |
| IMDX | Insight Molecular Diagnos… | $6.01 | 172.27M | +228% | -74% | — | — | -0.84 | -4.15 | 27.10 | -0.78 | -3.46 | -1.90 | 39.34% | -3245.14% | -3225.04% | -1480.67% | 3654.06% | -110.32% | -0.30 | -726.68 | 1.62 | 1.41 | 0.08 | 2430.00% | 2515.00% | -1007.00% | -41.64% | -2.85 | 1270.82% | 0.00% | 0.00% | 0.00% | -0.75 | -2.17 | 24.46 | -18.88 |
| IPHA | Innate Pharma S.A. | $1.72 | 160.74M | +2,263% | -50% | — | +2,571% | -2.98 | 16.70 | 11.69 | -2.08 | -0.52 | 16.70 | 100.00% | -408.64% | -391.97% | -162.91% | 247.94% | -34.57% | 3.51 | -91.12 | 2.60 | 2.50 | 0.75 | 57778.00% | -7568.00% | -7913.00% | -4.94% | -0.21 | 35.03% | 0.00% | 0.00% | 3.18% | -1.90 | -13.41 | 7.74 | -4.85 |
| IVVD | Invivyd, Inc. | $1.69 | 224.31M | — | — | — | — | -0.70 | 1.77 | 4.72 | -0.30 | — | 1.77 | 93.63% | -696.80% | -669.42% | -138.71% | 1644.29% | -94.75% | 0.02 | — | 1.62 | 1.30 | 0.39 | -2099.00% | — | -181.00% | -142.50% | -2.75 | 1586.23% | 0.00% | 0.00% | 0.00% | -0.29 | -0.30 | 2.04 | -12.54 |
| MIST | Milestone Pharmaceuticals… | $1.71 | 145.64M | +1,960% | — | — | — | -2.76 | 8.71 | — | -2.63 | — | 8.71 | 0.00% | — | — | -277.55% | -10631.82% | -55.09% | 4.17 | 11.76 | 9.10 | 8.87 | -0.78 | -5180.00% | -10000.00% | -3794.00% | -25.23% | -3.55 | -7293.18% | 0.00% | 0.00% | 7.45% | -2.36 | -3.45 | — | -6.51 |
| RANI | Rani Therapeutics Holding… | $1.37 | 100M | — | -55% | — | — | -0.79 | 22.30 | 43.21 | -0.92 | — | 22.30 | 100.00% | -5186.19% | -2920.04% | -761.66% | 7052.12% | -119.69% | 14.91 | -10.59 | 1.50 | 1.41 | -0.51 | -2105.00% | — | -3183.00% | -80.51% | -1.78 | 4730.69% | 0.00% | 0.00% | 0.00% | -0.87 | -1.30 | 45.23 | -7.58 |
| SGMO | Sangamo Therapeutics, Inc… | $0.43 | 160.68M | +6,900% | -3% | — | +6,207% | -2.14 | 9.21 | 3.63 | -2.23 | — | 9.21 | 100.00% | -179.88% | -169.45% | -185.39% | -403.81% | -73.38% | 1.34 | — | 1.13 | 1.02 | 0.13 | -6689.00% | -6720.00% | -7260.00% | -32.13% | -1.47 | -262.24% | 0.00% | 0.00% | 2.03% | -1.91 | -2.94 | 3.43 | -21.86 |
| TARA | Protara Therapeutics, Inc… | $6.36 | 245.43M | — | — | — | — | -1.86 | 0.50 | — | 1.70 | — | 0.51 | 0.00% | — | — | -37.88% | -1031.24% | -34.25% | 0.03 | — | 15.71 | 15.54 | 3.24 | -3922.00% | — | -460.00% | -43.33% | -3.27 | -752.56% | 0.00% | 0.00% | 150.03% | 1.69 | 2.31 | — | 1.75 |
About OmniAb, Inc.
OmniAb, Inc., a biotechnology company, provides therapeutic antibody discovery technologies in the United States. The company's discovery platform provides industry partners access to the diverse antibody repertoires and screening technologies to enable discovery of next-generation therapeutics. Its OmniAb platform is the biological intelligence of proprietary transgenic animals, including OmniRat, OmniChicken, and OmniMouse that have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates. The company's OmniFlic (transgenic rat) and OmniClic (transgenic chicken) address industry needs for bispecific antibody applications though a common light chain approach, and OmniTaur that features unique structural attributes of cow antibodies for complex targets. The company was founded in 2012 and is headquartered in Emeryville, California.
- CEO
- Matthew W. Foehr
- Employees
- 114
- Beta
- 0.85
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($1.77 ÷ $1.40) − 1 = +26.43% (DCF, example).